Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Free Survival ◽

Baseline Population Characteristics And The Association Between Progression-Free Survival And Overall Survival In Advanced Non-Small Cell Lung Cancer Patients

Value in Health ◽

10.1016/j.jval.2017.08.134 ◽

2017 ◽

Vol 20 (9) ◽

pp. A420-A421

Author(s):

M Kulakova ◽

M Hashim ◽

B Pfeiffer ◽

M Postma ◽

B Heeg

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Population Characteristics ◽

Small Cell Lung ◽

Free Survival ◽

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies

10.1016/j.jtho.2016.07.017 ◽

2016 ◽

Vol 11 (11) ◽

pp. 1927-1939 ◽

Cited By ~ 29

Author(s):

Takehito Shukuya ◽

Keita Mori ◽

Joseph M. Amann ◽

Erin M. Bertino ◽

Gregory A. Otterson ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

P3.01-05 Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy

10.1016/j.jtho.2018.08.1565 ◽

2018 ◽

Vol 13 (10) ◽

pp. S868-S869

Author(s):

P. Bhatt ◽

P. Bonomi ◽

S. Basu ◽

M. Batus

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations

Journal of Thoracic Disease ◽

10.21037/jtd.2017.07.107 ◽

2017 ◽

Vol 9 (9) ◽

pp. 2923-2934 ◽

Cited By ~ 9

Author(s):

Ting Ding ◽

Fei Zhou ◽

Xiaoxia Chen ◽

Shijia Zhang ◽

Yinan Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Acquired Resistance ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib

10.1158/1538-7445.am2016-856 ◽

2016 ◽

Author(s):

Emma Pailler ◽

Marianne Oulhen ◽

Kirsty Ross ◽

Fanny Billiot ◽

Nathalie Auger ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non–Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements

Clinical Lung Cancer ◽

10.1016/j.cllc.2013.04.008 ◽

2013 ◽

Vol 14 (5) ◽

pp. 592-595 ◽

Cited By ~ 26

Author(s):

Jonathan W. Riess ◽

Sukhmani K. Padda ◽

Charles D. Bangs ◽

Millie Das ◽

Joel W. Neal ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Case Series ◽

Small Cell ◽

Gene Rearrangements ◽

Small Cell Lung ◽

Free Survival ◽

Mature progression-free survival (PFS) milestones in real world stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) +/- bevacizumab(Bev) followed by pem +/-bev maintenance.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21063 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21063-e21063

Author(s):

Parva Kiran Bhatt ◽

Philip D. Bonomi ◽

Sanjib Basu ◽

Mary J. Fidler ◽

Marta Batus

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Real World ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Free Survival ◽

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

Thoracic Cancer ◽

10.1111/1759-7714.12986 ◽

2019 ◽

Vol 10 (4) ◽

pp. 686-694

Author(s):

Yingying Pan ◽

Guanghui Gao ◽

Xiaoxia Chen ◽

Qinrui Tian ◽

Fengying Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Egfr Mutation ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Free Survival ◽

Egfr Tyrosine Kinase Inhibitors

MA11.03 Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients

10.1016/j.jtho.2019.08.585 ◽

2019 ◽

Vol 14 (10) ◽

pp. S291

Author(s):

O.G. Arrieta ◽

F. Barrón ◽

A. Carmona ◽

L. Ramírez-Tirado ◽

Z.L. Zatarain Barrón ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

Lung Cancer Patients ◽

Previously Treated

84P Impact of PTV on progression-free survival in inoperable stage III non-small cell lung cancer patients treated with chemoradioimmunotherapy

10.1016/s1556-0864(21)01926-2 ◽

2021 ◽

Vol 16 (4) ◽

pp. S741-S742

Author(s):

J. Taugner ◽

M. Karin ◽

L. Kaesmann ◽

C. Eze ◽

B. Flörsch ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Small Cell ◽

Stage Iii ◽

Small Cell Lung ◽

Free Survival ◽